Susquehanna International Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-61,400
| Closed | -$301K | – | 14443 |
|
|
2021
Q3 | $301K | Buy |
61,400
+800
| +1% | +$3.88K | ﹤0.01% | 10597 |
|
|
2021
Q2 | $320K | Sell |
60,600
-40,000
| -40% | -$207K | ﹤0.01% | 10639 |
|
|
2021
Q1 | $483K | Buy |
+100,600
| New | +$525K | ﹤0.01% | 9555 |
|
|
2020
Q4 | – | Sell |
-18,400
| Closed | -$76K | – | 11991 |
|
|
2020
Q3 | $76K | Buy |
18,400
+4,700
| +34% | +$18.2K | ﹤0.01% | 10060 |
|
|
2020
Q2 | $35K | Buy |
+13,700
| New | +$40.3K | ﹤0.01% | 9841 |
|
|
2020
Q1 | – | Sell |
-30,000
| Closed | -$114K | – | 11174 |
|
|
2019
Q4 | $114K | Sell |
30,000
-75,500
| -72% | -$361K | ﹤0.01% | 9084 |
|
|
2019
Q3 | $540K | Buy |
105,500
+75,100
| +247% | +$464K | ﹤0.01% | 7130 |
|
|
2019
Q2 | $188K | Sell |
30,400
-900
| -3% | -$5.18K | ﹤0.01% | 9177 |
|
|
2019
Q1 | $223K | Sell |
31,300
-30,000
| -49% | -$270K | ﹤0.01% | 7721 |
|
|
2018
Q4 | $524K | Sell |
61,300
-24,100
| -28% | -$313K | ﹤0.01% | 5956 |
|
|
2018
Q3 | $1.71M | Sell |
85,400
-28,700
| -25% | -$674K | ﹤0.01% | 4254 |
|
|
2018
Q2 | $2.95M | Sell |
114,100
-120,500
| -51% | -$3.34M | ﹤0.01% | 3412 |
|
|
2018
Q1 | $5.61M | Buy |
234,600
+87,000
| +59% | +$2.74M | ﹤0.01% | 2407 |
|
|
2017
Q4 | $5M | Buy |
+147,600
| New | +$4.12M | ﹤0.01% | 2539 |
|
|
2017
Q3 | – | Sell |
-24,900
| Closed | -$436K | – | 9931 |
|
|
2017
Q2 | $436K | Buy |
24,900
+12,000
| +93% | +$198K | ﹤0.01% | 6899 |
|
|
2017
Q1 | $226K | Sell |
12,900
-3,800
| -23% | -$64.8K | ﹤0.01% | 7836 |
|
|
2016
Q4 | $282K | Buy |
+16,700
| New | +$258K | ﹤0.01% | 8091 |
|
Susquehanna International Group's ADMS Position: Q4 2021 in Review
Susquehanna International Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 38,545 shares — an estimated $189K sold.
Susquehanna International Group first reported a position in ADMS in Q4 2015 and held it in 14 quarters. The position peaked at $4.56M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Susquehanna International Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Susquehanna International Group sold 38,545 Adamas Pharmaceuticals shares in Q4 2021, an estimated $189K.
- Susquehanna International Group first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 14 quarters.
- Susquehanna International Group's Adamas Pharmaceuticals position peaked at $4.56M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.